Jaguar Health, Inc.
crofelemer
rare intestinal failure diseases
Resolved
7days ago
Advisory committee · ~ Jun 30, 2026 estimated
What's at stake
An FDA advisory committee reviews crofelemer for rare intestinal failure diseases around ~ Jun 30, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“the Company for our crofelemer-based prescription drug candidate for rare intestinal failure diseases.”